Eupraxia Pharmaceuticals Inc. (EPRX)Healthcare | Biotechnology | Victoria, Canada | NasdaqCM
7.10 USD
-0.10
(-1.389%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 7.24 +0.14 (1.972%) ⇧ (April 17, 2026, 6:30 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:04 p.m. EDT
EPRX exhibits mixed signals for short-term trading, with a modest upward prediction of 1.23% in the next 45 days, but the price has been volatile and below the 52-week average. The stock is currently trading at a discount relative to its 52-week high, suggesting potential for a rebound. However, the lack of recent dividends and negative earnings indicate a lack of financial stability, making it a risky short-term play. For long-term investors, the stock's fundamentals are weak with negative earnings and low return on equity, which suggests it is not a solid long-term investment. Overall, EPRX appears to be a speculative opportunity rather than a reliable investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.129663 |
| AutoETS | 0.133247 |
| AutoTheta | 0.171898 |
| AutoARIMA | 0.193551 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 15.25 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.396 |
| Excess Kurtosis | -0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.192 |
| Market Cap | 436,672,576 |
| Forward P/E | -11.05 |
| Beta | 1.42 |
| Website | https://www.eupraxiapharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0689654 |
| Address1 | 2,067 Cadboro Bay Road |
| Address2 | Suite 201 |
| All Time High | 9.32 |
| All Time Low | 2.2 |
| Ask | 7.16 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 170,210 |
| Average Daily Volume3 Month | 223,265 |
| Average Volume | 223,265 |
| Average Volume10Days | 170,210 |
| Beta | 1.416 |
| Bid | 7.0 |
| Bid Size | 1 |
| Book Value | 1.007 |
| City | Victoria |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.1 |
| Current Ratio | 15.121 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.38 |
| Day Low | 7.04 |
| Debt To Equity | 0.192 |
| Display Name | Eupraxia Pharmaceuticals |
| Earnings Timestamp End | 1,778,097,600 |
| Earnings Timestamp Start | 1,778,097,600 |
| Ebitda | -38,269,636 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.205 |
| Enterprise Value | 390,556,768 |
| Eps Current Year | -0.71667 |
| Eps Forward | -0.6425 |
| Eps Trailing Twelve Months | -1.03 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.6856 |
| Fifty Day Average Change | -0.5855999 |
| Fifty Day Average Change Percent | -0.07619443 |
| Fifty Two Week Change Percent | 106.896545 |
| Fifty Two Week High | 9.32 |
| Fifty Two Week High Change | -2.2199998 |
| Fifty Two Week High Change Percent | -0.23819742 |
| Fifty Two Week Low | 3.38 |
| Fifty Two Week Low Change | 3.7199998 |
| Fifty Two Week Low Change Percent | 1.1005917 |
| Fifty Two Week Range | 3.38 - 9.32 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,712,323,800,000 |
| Float Shares | 45,627,364 |
| Forward Eps | -0.6425 |
| Forward P E | -11.050584 |
| Free Cashflow | -16,298,055 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 49 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14797 |
| Held Percent Institutions | 0.30922002 |
| Implied Shares Outstanding | 61,503,180 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-04-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. |
| Long Name | Eupraxia Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 436,672,576 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_225412256 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -41,106,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 440,252,466 |
| Number Of Analyst Opinions | 7 |
| Open | 7.38 |
| Operating Cashflow | -28,552,218 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 250 590 3968 |
| Post Market Change | 0.13999987 |
| Post Market Change Percent | 1.9718292 |
| Post Market Price | 7.24 |
| Post Market Time | 1,776,465,056 |
| Previous Close | 7.2 |
| Price Eps Current Year | -9.906931 |
| Price Hint | 2 |
| Price To Book | 7.050646 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.435 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.099999905 |
| Regular Market Change Percent | -1.3888876 |
| Regular Market Day High | 7.38 |
| Regular Market Day Low | 7.04 |
| Regular Market Day Range | 7.04 - 7.38 |
| Regular Market Open | 7.38 |
| Regular Market Previous Close | 7.2 |
| Regular Market Price | 7.1 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 85,763 |
| Return On Assets | -0.39674 |
| Return On Equity | -0.68764 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 61,503,180 |
| Shares Percent Shares Out | 0.041300002 |
| Shares Short | 2,500,950 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,979,996 |
| Short Name | Eupraxia Pharmaceuticals Inc. |
| Short Ratio | 10.97 |
| Source Interval | 15 |
| State | BC |
| Symbol | EPRX |
| Target High Price | 19.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 14.39286 |
| Target Median Price | 14.0 |
| Total Cash | 80,563,480 |
| Total Cash Per Share | 1.31 |
| Total Debt | 154,362 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.03 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.55917 |
| Two Hundred Day Average Change | 0.54083014 |
| Two Hundred Day Average Change Percent | 0.082454056 |
| Type Disp | Equity |
| Volume | 85,763 |
| Website | https://www.eupraxiapharma.com |
| Zip | V8R 5G4 |